{
  "main_header": {
    "sid": 286243,
    "name": "Parnax Lab",
    "stock_name": "Parnax Lab",
    "full_name": "Parnax Lab Ltd",
    "name_url": "stocks-analysis/parnax-lab",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "113.15",
    "chg": -6.9,
    "chgp": "-5.75%",
    "dir": -1,
    "prev_price": "120.05",
    "mcapval": "137.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 506128,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 49,
    "indexname": "",
    "isin": "INE383L01019",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "7.42 k",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/parnax-lab-286243-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Parnax Lab falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-parnax-lab-fallingrising-3744844",
        "imagepath": "",
        "date": "2025-12-04 00:27:35",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Performance</strong></p>\n<p>Parnax Lab’s share price has been on a consistent slide, registering losses for nine consecutive trading sessions. Over this period, the stock has declined by 11.37%, signalling persistent selling pressure. The latest session opened with a significant gap down of 6.09%, reflecting negative investor sentiment from the outset. Despite an intraday high of ₹121.85, which represented a 3.09% gain from the previous close, the stock ultimately succumbed to selling pressure, touching a low of ₹110, down 6.94% intraday. The wide trading range of ₹11.85 and an intraday volatility of 5.11% underscore the heightened uncertainty and price fluctuations experienced by investors today.</p>\n<p><strong>Technical Indicators and Trading Volumes</stron..."
      },
      {
        "title": "Parnax Lab Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/parnax-lab-upgraded-to-hold-as-technicals-improve-amid-mixed-financials-3740251",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/ParnaxLab_mojoScore_3740251.png",
        "date": "2025-12-02 08:09:00",
        "description": "Parnax Lab, a player in the Pharmaceuticals & Biotechnology sector, has experienced a notable revision in its market evaluation, reflecting a complex interplay of technical indicators, financial performance, valuation metrics, and broader market trends. This article analyses the key factors influencing the recent shift in the company’s assessment and what it means for investors navigating the current market environment."
      },
      {
        "title": "How has been the historical performance of Parnax Lab?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-parnax-lab-3739164",
        "imagepath": "",
        "date": "2025-12-01 23:00:11",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Operating Performance Trends</strong></p>\n<p>Examining Parnax Lab’s consolidated financials from fiscal year ending March 2019 through March 2025 reveals a notable expansion in net sales. The company’s revenue nearly doubled from under ₹110 crores in 2019 to approximately ₹188 crores by March 2025. This growth was particularly pronounced after fiscal 2021, where sales surged from ₹89.52 crores to over ₹160 crores in subsequent years, reflecting a strong recovery and market demand.</p>\n<p>Operating profit margins have also improved significantly. The operating profit margin excluding other income rose from 9.4% in 2019 to a robust 14.26% in 2025, indicating enhanced operational efficiency and cost management. Operating profit (PBDIT) increased from ₹10.22 crores in 2019 to ₹28.45 ..."
      },
      {
        "title": "Parnax Lab’s Market Assessment Reflects Mixed Signals Amidst Financial and Technical Shifts",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/parnax-lab-downgraded-to-sell-amid-mixed-financials-and-weak-technicals-3727552",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ParnaxLab_mojoScore_3727552.png",
        "date": "2025-11-25 08:09:12",
        "description": "Parnax Lab, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable revision in its market evaluation, reflecting a complex interplay of financial performance, valuation metrics, and technical indicators. This article analyses the recent shifts across four critical parameters shaping the company’s current market standing."
      },
      {
        "title": "Are Parnax Lab latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-parnax-lab-latest-results-good-or-bad-3712652",
        "imagepath": "",
        "date": "2025-11-18 19:28:59",
        "description": "Parnax Lab's latest financial results for the quarter ending September 2025 demonstrate a notable revenue momentum, with net sales reaching ₹62.60 crores, reflecting a 17.27% quarter-on-quarter growth and a substantial 29.45% year-on-year increase. This marks the highest quarterly sales in the company's recent history, indicating effective market penetration or increased demand for its products.\n\nHowever, the financial performance also reveals challenges, particularly in profitability. The operating profit margin has contracted to 12.89%, down from 13.94% in the previous quarter and 14.97% a year earlier. This margin compression raises concerns about the company's cost management and pricing power amidst a competitive pharmaceutical landscape. The net profit for the quarter was ₹3.63 crores, showing an 11.01% increase from the previous quarter but a decline of 6.45% year-on-year, suggesting that while reven..."
      },
      {
        "title": "How has been the historical performance of Parnax Lab?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-parnax-lab-3708518",
        "imagepath": "",
        "date": "2025-11-17 22:53:15",
        "description": "Answer:\nThe historical performance of Parnax Lab shows a gradual improvement in financial metrics over the years, with notable growth in net profit and operating income.\n\nBreakdown:\nParnax Lab's net sales have shown a steady increase from INR 89.52 crore in March 2021 to INR 187.74 crore in March 2025, despite a slight decline from INR 188.71 crore in March 2024. Total operating income has similarly risen, reaching INR 187.74 crore in March 2025, up from INR 89.52 crore in March 2021. The company's operating profit (PBDIT) has also improved significantly, climbing from INR 10.16 crore in March 2021 to INR 28.45 crore in March 2025. Profit before tax has turned positive, moving from a loss of INR 1.97 crore in March 2020 to a profit of INR 15.67 crore in March 2025. Consequently, profit after tax has increased from a loss of INR 2.92 crore in March 2020 to INR 11.54 crore in March 2025. The company's total a..."
      },
      {
        "title": "Parnax Lab Q2 FY26: Strong Revenue Surge Masks Margin Pressures",
        "link": "https://www.marketsmojo.com/news/result-analysis/parnax-lab-q2-fy26-strong-revenue-surge-masks-margin-pressures-3709396",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ParnaxLab_quaterlyResult_3709396.png",
        "date": "2025-11-17 21:52:23",
        "description": "Parnax Lab Limited, a micro-cap pharmaceutical formulations manufacturer, reported mixed results for Q2 FY26, with net profit rising 11.01% quarter-on-quarter to ₹3.63 crores but declining 6.45% year-on-year from ₹3.41 crores in Q2 FY25. The company's market capitalisation stands at ₹155.00 crores, with shares trading at ₹129.55 as of November 17, 2025."
      },
      {
        "title": "How has been the historical performance of Parnax Lab?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-parnax-lab-3702858",
        "imagepath": "",
        "date": "2025-11-14 23:35:59",
        "description": "Answer:\nThe historical performance of Parnax Lab shows a gradual improvement in key financial metrics over the years, particularly from March 2021 to March 2025.\n\nBreakdown:\nParnax Lab's net sales have shown a steady increase from INR 89.52 crore in March 2021 to INR 187.74 crore in March 2025, with a slight decline in the last year from INR 188.71 crore in March 2024. Total operating income followed a similar trend, reaching INR 187.74 crore in March 2025. The company's operating profit (PBDIT) has also improved significantly, rising from INR 9.95 crore in March 2021 to INR 28.45 crore in March 2025. Profit before tax increased from a loss of INR 0.08 crore in March 2021 to a profit of INR 15.67 crore in March 2025, while profit after tax rose from a loss of INR 0.36 crore to a profit of INR 11.54 crore in the same period. The earnings per share (EPS) improved from a negative INR 0.42 in March 2021 to INR ..."
      },
      {
        "title": "Is Parnax Lab overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-parnax-lab-overvalued-or-undervalued-3687499",
        "imagepath": "",
        "date": "2025-11-11 08:07:54",
        "description": "As of 10 November 2025, Parnax Lab's valuation grade has moved from fair to attractive, indicating a more favorable assessment of its stock. The company is currently considered undervalued, supported by a PE ratio of 13.34, an EV to EBITDA of 8.24, and a ROE of 13.86%. In comparison to its peers, Parnax Lab's valuation stands out against Elitecon International, which is deemed very expensive with a PE ratio of 359.8, and PTC India, which is classified as very attractive with a PE ratio of 7.89.\n\nDespite recent stock performance showing a decline of 25.27% year-to-date compared to a 6.91% gain in the Sensex, Parnax Lab's strong financial ratios and improved valuation grade suggest that it may present a compelling investment opportunity. The company's solid fundamentals, including a PEG ratio of 2.54, further reinforce the notion that it is undervalued relative to its peers in the pharmaceuticals and biotechn..."
      }
    ],
    "total": 248,
    "sid": "286243",
    "stock_news_url": "https://www.marketsmojo.com/news/parnax-lab-286243"
  },
  "announcements": [
    {
      "caption": "Results For The Quarter Ended September 30 2025",
      "datetime": "14-Nov-2025",
      "details": "Please find enclosed herewith the Results for the Quarter and Half Year ended September 30 2025.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of Board Meeting Dated 14Th November 2025",
      "datetime": "14-Nov-2025",
      "details": "Outcome of Board Meeting dated 14th November 2025",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Consideration And Approval Of Standalone And Consolidated Un-Audited IND- AS Compliant Financial Results Along With Limited Review Report For The Quarter (Q2) And Half Year Ended 30Th September 2025.",
      "datetime": "03-Nov-2025",
      "details": "Parnax Lab Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 inter alia to consider and approve consider and approve Standalone and Consolidated Un-audited IND- AS Compliant Financial Results along with Limited Review Report for the quarter (Q2) and half year ended 30th September 2025 pursuant to Regulation 33 of Listing Obligation and Disclosure Requirement 2015.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Parnax Lab falling/rising?

2025-12-04 00:27:35

Recent Price Movement and Market Performance

Parnax Lab’s share price has been on a consistent slide, registering losses for nine consecutive trading sessions. Over this period, the stock has declined by 11.37%, signalling persistent selling pressure. The latest session opened with a significant gap down of 6.09%, reflecting negative investor sentiment from the outset. Despite an intraday high of ₹121.85, which represented a 3.09% gain from the previous close, the stock ultimately succumbed to selling pressure, touching a low of ₹110, down 6.94% intraday. The wide trading range of ₹11.85 and an intraday volatility of 5.11% underscore the heightened uncertainty and price fluctuations experienced by investors today.

Technical Indicators and Trading VolumesRead More

Parnax Lab Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals

2025-12-02 08:09:00

Parnax Lab, a player in the Pharmaceuticals & Biotechnology sector, has experienced a notable revision in its market evaluation, reflecting a complex interplay of technical indicators, financial performance, valuation metrics, and broader market trends. This article analyses the key factors influencing the recent shift in the company’s assessment and what it means for investors navigating the current market environment.

Read More

How has been the historical performance of Parnax Lab?

2025-12-01 23:00:11

Revenue and Operating Performance Trends

Examining Parnax Lab’s consolidated financials from fiscal year ending March 2019 through March 2025 reveals a notable expansion in net sales. The company’s revenue nearly doubled from under ₹110 crores in 2019 to approximately ₹188 crores by March 2025. This growth was particularly pronounced after fiscal 2021, where sales surged from ₹89.52 crores to over ₹160 crores in subsequent years, reflecting a strong recovery and market demand.

Operating profit margins have also improved significantly. The operating profit margin excluding other income rose from 9.4% in 2019 to a robust 14.26% in 2025, indicating enhanced operational efficiency and cost management. Operating profit (PBDIT) increased from ₹10.22 crores in 2019 to ₹28.45 ...

Read More

Parnax Lab’s Market Assessment Reflects Mixed Signals Amidst Financial and Technical Shifts

2025-11-25 08:09:12

Parnax Lab, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable revision in its market evaluation, reflecting a complex interplay of financial performance, valuation metrics, and technical indicators. This article analyses the recent shifts across four critical parameters shaping the company’s current market standing.

Read More

Are Parnax Lab latest results good or bad?

2025-11-18 19:28:59

Parnax Lab's latest financial results for the quarter ending September 2025 demonstrate a notable revenue momentum, with net sales reaching ₹62.60 crores, reflecting a 17.27% quarter-on-quarter growth and a substantial 29.45% year-on-year increase. This marks the highest quarterly sales in the company's recent history, indicating effective market penetration or increased demand for its products. However, the financial performance also reveals challenges, particularly in profitability. The operating profit margin has contracted to 12.89%, down from 13.94% in the previous quarter and 14.97% a year earlier. This margin compression raises concerns about the company's cost management and pricing power amidst a competitive pharmaceutical landscape. The net profit for the quarter was ₹3.63 crores, showing an 11.01% increase from the previous quarter but a decline of 6.45% year-on-year, suggesting that while reven...

Read More

How has been the historical performance of Parnax Lab?

2025-11-17 22:53:15

Answer: The historical performance of Parnax Lab shows a gradual improvement in financial metrics over the years, with notable growth in net profit and operating income. Breakdown: Parnax Lab's net sales have shown a steady increase from INR 89.52 crore in March 2021 to INR 187.74 crore in March 2025, despite a slight decline from INR 188.71 crore in March 2024. Total operating income has similarly risen, reaching INR 187.74 crore in March 2025, up from INR 89.52 crore in March 2021. The company's operating profit (PBDIT) has also improved significantly, climbing from INR 10.16 crore in March 2021 to INR 28.45 crore in March 2025. Profit before tax has turned positive, moving from a loss of INR 1.97 crore in March 2020 to a profit of INR 15.67 crore in March 2025. Consequently, profit after tax has increased from a loss of INR 2.92 crore in March 2020 to INR 11.54 crore in March 2025. The company's total a...

Read More

Parnax Lab Q2 FY26: Strong Revenue Surge Masks Margin Pressures

2025-11-17 21:52:23

Parnax Lab Limited, a micro-cap pharmaceutical formulations manufacturer, reported mixed results for Q2 FY26, with net profit rising 11.01% quarter-on-quarter to ₹3.63 crores but declining 6.45% year-on-year from ₹3.41 crores in Q2 FY25. The company's market capitalisation stands at ₹155.00 crores, with shares trading at ₹129.55 as of November 17, 2025.

Read More

How has been the historical performance of Parnax Lab?

2025-11-14 23:35:59

Answer: The historical performance of Parnax Lab shows a gradual improvement in key financial metrics over the years, particularly from March 2021 to March 2025. Breakdown: Parnax Lab's net sales have shown a steady increase from INR 89.52 crore in March 2021 to INR 187.74 crore in March 2025, with a slight decline in the last year from INR 188.71 crore in March 2024. Total operating income followed a similar trend, reaching INR 187.74 crore in March 2025. The company's operating profit (PBDIT) has also improved significantly, rising from INR 9.95 crore in March 2021 to INR 28.45 crore in March 2025. Profit before tax increased from a loss of INR 0.08 crore in March 2021 to a profit of INR 15.67 crore in March 2025, while profit after tax rose from a loss of INR 0.36 crore to a profit of INR 11.54 crore in the same period. The earnings per share (EPS) improved from a negative INR 0.42 in March 2021 to INR ...

Read More

Is Parnax Lab overvalued or undervalued?

2025-11-11 08:07:54

As of 10 November 2025, Parnax Lab's valuation grade has moved from fair to attractive, indicating a more favorable assessment of its stock. The company is currently considered undervalued, supported by a PE ratio of 13.34, an EV to EBITDA of 8.24, and a ROE of 13.86%. In comparison to its peers, Parnax Lab's valuation stands out against Elitecon International, which is deemed very expensive with a PE ratio of 359.8, and PTC India, which is classified as very attractive with a PE ratio of 7.89. Despite recent stock performance showing a decline of 25.27% year-to-date compared to a 6.91% gain in the Sensex, Parnax Lab's strong financial ratios and improved valuation grade suggest that it may present a compelling investment opportunity. The company's solid fundamentals, including a PEG ratio of 2.54, further reinforce the notion that it is undervalued relative to its peers in the pharmaceuticals and biotechn...

Read More

View All News